ICUMEDIUM SIGNALREGULATORY/FINANCIAL10-K

ICU Medical expanded its FDA breakthrough device designations from four to six therapeutic indications while demonstrating meaningful improvement in operating losses and debt reduction.

The company secured two additional FDA breakthrough device designations, expanding coverage to include systemic inflammatory response during cardiac surgery and cardiorenal syndrome patients, which broadens the addressable market for their SCD therapy. The formal naming of their pivotal trial as "NEUTRALIZE-AKI" suggests progression toward regulatory milestones, while the addition of a new feasibility study in cardiorenal syndrome patients indicates therapeutic expansion.

Comparing 2026-03-25 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

ICU Medical showed meaningful operational improvement with operating losses narrowing by approximately one-third and net losses improving substantially year-over-year. The company reduced total debt by nearly half to $4.1M and cut interest expense by over three-quarters, strengthening its balance sheet position. R&D spending declined modestly to $7.5M while operating cash flow burn improved by 15%, indicating more efficient capital deployment as the company advances its clinical programs.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-77.4%
$1.1M→$244K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
+51.1%
-$24.8M→-$12.2M

Net income grew 51.1% — bottom-line growth signals improving overall business health.

Total Debt
Balance Sheet
-45.9%
$7.7M→$4.1M

Debt reduced 45.9% — deleveraging strengthens balance sheet and reduces financial risk.

Total Liabilities
Balance Sheet
-45.3%
$6.8M→$3.7M

Liabilities reduced 45.3% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-45.3%
$6.8M→$3.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
+34.3%
$38K→$52K

Cash position surged 34.3% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
+31.8%
-$17.8M→-$12.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

R&D Expense
P&L
-17.4%
$9.1M→$7.5M

R&D spending cut 17.4% — could signal cost discipline or concerning reduction in innovation investment.

Operating Cash Flow
Cash Flow
+15%
-$16.0M→-$13.6M

Operating cash flow grew 15% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-27
ADDED
We anticipate that we will file the 2026 proxy statement on or before April 29, 2026.
In addition, we are currently conducting a pivotal clinical trial, also referred to as "NEUTRALIZE-AKI" to assess the safety and efficacy of the SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy ( CRRT ).
We are also conducting a feasibility study of the SCD therapy in adult patients with Cardiorenal Syndrome ("CRS") awaiting left ventricular assist device ("LVAD") implantation.
Our SCD therapy has been awarded six Breakthrough Device Designations ( BDD ) by the FDA.
These BDDs cover multiple therapeutic indications for the use of our SCD therapy in adult patients with AKI, CRS awaiting LVAD implantation, hepatorenal syndrome, end stage renal disease ( ESRD ), and systemic inflammatory response while undergoing cardiac surgery.
+7 more — sign up free →
REMOVED
We anticipate that we will file the 2024 proxy statement on or before April 29, 2025.
In addition, we are currently conducting a pivotal clinical trial to assess the safety and efficacy of the SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy ( CRRT ).
Our SCD therapy has been awarded Breakthrough Device Designation ( BDD ) for four therapeutic indications by the FDA, including the use of the SCD therapy for adult patients with AKI, patients with cardiorenal syndrome awaiting left ventricular assist device ( LVAD ) implantation, patients with hepatorenal syndrome, and patients with end stage renal disease ( ESRD ).
Preclinically, we evaluated our SCD therapy in various animal models representing multiple hyperinflammatory indications, including acute myocardial infarction, intracranial hemorrhage, chronic heart failure, sepsis, and acute respiratory distress syndrome.
Our senior management team and Board have an average of over 19 years of experience in the healthcare industry, including expertise in regulatory and medical affairs, commercialization and distribution in our initial therapeutic priority areas.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →